Nitric Oxide Release Combined with Nonsteroidal Antiinflammatory Activity Prevents Muscular Dystrophy Pathology and Enhances Stem Cell Therapy.
From: Department of Experimental Medicine, University of Milano-Bicocca, 20052 Monza, Italy.
Proceedings of the National Academy of Sciences of the United States of America
- Publish Date: Jan 2007
- ISSN: 0027-8424
- Volume: 104
- Issue: 1
- Pages: 264-9
- Medium: Print
- Language: English
- Citation (JAMA): Brunelli Silvia, Sciorati Clara, D'Antona Giuseppe, et al. Nitric Oxide Release Combined with Nonsteroidal Antiinflammatory Activity Prevents Muscular Dystrophy Pathology and Enhances Stem Cell Therapy.. Proc. Natl. Acad. Sci. U.S.A. Jan 2007;104:264-9
Abstract
Duchenne muscular dystrophy is a relatively common disease that affects skeletal muscle, leading to progressive paralysis and death. There is currently no resolutive therapy. We have developed a treatment in which we combined the effects of nitric oxide with nonsteroidal antiinflammatory activity by using HCT 1026, a nitric oxide-releasing derivative of flurbiprofen. Here, we report the results of long-term (1-year) oral treatment with HCT 1026 of two murine models for limb girdle and Duchenne muscular dystrophies (alpha-sarcoglycan-null and mdx mice). In both models, HCT 1026 significantly ameliorated the morphological, biochemical, and functional phenotype in the absence of secondary effects, efficiently slowing down disease progression. HCT 1026 acted by reducing inflammation, preventing muscle damage, and preserving the number and function of satellite cells. HCT 1026 was significantly more effective than the corticosteroid prednisolone, which was analyzed in parallel. As an additional beneficial effect, HCT 1026 enhanced the therapeutic efficacy of arterially delivered donor stem cells, by increasing 4-fold their ability to migrate and reconstitute muscle fibers. The therapeutic strategy we propose is not selective for a subset of mutations; it provides ground for immediate clinical experimentation with HCT 1026 alone, which is approved for use in humans; and it sets the stage for combined therapies with donor or autologous, genetically corrected stem cells.
Mesh Headings (Keywords): Animals, Anti-Inflammatory Agents, Non-Steroidal, Apoptosis, Combined Modality Therapy, Creatine Kinase, Flurbiprofen, Mice, Muscle, Skeletal, Muscular Dystrophy, Animal, Muscular Dystrophy, Duchenne, Nitric Oxide Donors, Prednisolone, Regeneration, Sarcoglycans, Stem Cell Transplantation
Check for Full Text / PubMed Unique Identifier (PMID): 17182743
This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.
Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.
The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.